/PRNewswire/ ViewRay, Inc. (NASDAQ: VRAY) today announced the first toxicity results from the prospective single-arm Phase II SCIMITAR trial. A secondary.
A remarkable reduction in bowel and urinary side effects was reported when MRI was used instead of CT to guide stereotactic body radiotherapy for localized prostate cancer.